FDA Brief

Warning letters Drugs

FDA warning letter to

PReye, LLC

High riskIssued Aug 18Posted Sep 1Center for Drug Evaluation and Research (CDER)

FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

What happened

FDA inspected PReye, LLC's drug repackaging site in Wheat Ridge, Colorado, from March 17 to 19, 2026, and found sterile eye drugs filled by hand in a small flow hood on a desk in an office with no HEPA air filtration. In June 2026 FDA also reviewed the company website and found claims that PReye Vitamin SEE prevents cataracts and macular degeneration, which makes it an unapproved new drug. The company recalled the product on May 18, 2026, because it had not been tested for sterility, and told FDA on March 22, 2026, that it would stop making and distributing it for the U.S. market.

What FDA found

  1. Sterile eye drugs were hand-filled in a non-certified flow hood on a desk in an unclassified office with no HEPA filtration, so nothing protected the product from microbes.

    21 CFR 211.42(c)(10) and 21 CFR 211.63
  2. The firm had no quality control unit and no written procedures for complaints, supplier qualification, release testing, change management, cleaning, disinfection, or deviations.

    21 CFR 211.22
  3. Sterile eye drug products made since 2024 were not given batch numbers, so they cannot be traced.

    21 CFR 211.22
  4. Website labeling claiming the eye drop prevents cataracts and macular degeneration makes it a new drug, and it is sold without an FDA-approved application.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  5. The firm's drug listing for PReye Vitamin SEE was not updated or certified, and FDA has made it inactive.

What FDA wants

FDA asks the firm to send a written response within 15 business days to CDER-OC-OMQ-Communications@fda.hhs.gov, marked with FEI 3031057987 and ATTN: Compliance Officer Nancy Scheraga. It also asks the firm to update or discontinue its drug listing, notify FDA before resuming any drug manufacturing, and engage a qualified consultant to audit the operation and check that corrections worked.

Who should pay attention

  • med spas and clinics that buy repackaged sterile drugs
  • repackers and compounding operations making ophthalmic or injectable drugs
  • suppliers and distributors that carried PReye Vitamin SEE

This is a summary. Read the original letter on fda.gov.

PReye, LLC's FDA history

Recalls in the last 12 months

Jul 1 Class II PReye LLC
Drug
PReye Vitamin See Antioxidant Preservative Free Eye Drops, Distributed by: PReye, LLC, Golden, CO
Lack of Assurance of Sterility

Full company page

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  4. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk